The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo

Journal of Dermatological Science

Volumn 77, Issue 1, 2015, Pages 74-76

  Keren, Aviad ^a   Shemer, Avner ^a   Ullmann, Yehuda ^a   Paus, Ralf ^b,c   Gilhar, Amos ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR ALPHA; KLRK1 PROTEIN, HUMAN; KLRK1 PROTEIN, MOUSE; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE;

ALOPECIA AREATA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; HAIR FOLLICLE; HAIR GROWTH; HUMAN; IN VIVO STUDY; LETTER; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMISTRY; CYTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; MOUSE; PILOT STUDY; SCID MOUSE; SKIN;

ALOPECIA AREATA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; LIGANDS; MICE; MICE, SCID; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PHOSPHODIESTERASE 4 INHIBITORS; PILOT PROJECTS; SKIN; THALIDOMIDE;

EID: 84930417518     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.11.009     Document Type: Letter

References (8)

1. Gilhar A., Keren A., Shemer A., Ullmann Y., Paus R. Blocking potassium channels (Kv1.3): a new treatment option for alopecia areata?. J Invest Dermatol 2013, 133:2088-2091.
2. Gilhar A., Keren A., Shemer A., d'Ovidio R., Ullmann Y., Paus R. Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J Invest Dermatol 2013, 133:844-847.
3. Bertolini M., Zilio F., Rossi A., Kleditzsch P., Emelianov V.E., Gilhar A., et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLOS ONE 2014, 9:e94260.
4. Gilhar A., Etzioni A., Paus R. Alopecia areata. N Engl J Med 2012, 366:1515-1525.
5. Petukhova L., Duvic M., Hordinsky M., Norris D., Price V., Shimomura Y., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-117.
6. Schafer P.H., Day R.M. Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4. J Am Acad Dermatol 2013, 68:1041-1042.
7. Poole R.M., Ballantyne A.D. Apremilast: first global approval. Drugs 2014, 74:825-837.
8. Ito T., Ito N., Bettermann A., Tokura Y., Takigawa M., Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol 2004, 164:623-634.